FIG 6.
(A to H) DIC and fluorescence micrographs of MRSA LAC-FCh cells treated for 3 h with either DMSO vehicle (A to D) or 4 μg/ml (4× MIC) TXA707 (E to H), followed by immunostaining using a PBP2a-specific monoclonal mouse antibody and a goat anti-mouse Alexa Fluor 488-conjugated secondary antibody prior to visualization. (I) Localization of PBP2a (green) and FtsZ (red) is schematically depicted, with the numbered arrows in the scheme reflecting the correspondingly numbered arrows in the florescence micrographs. Scale bars for panels A to H represent 2 μm. (J) Bar graph showing the prevalence of the various FtsZ and PBP2a phenotypes observed in both vehicle-treated cells (n = 536) and TXA707-treated cells (n = 315). Each percentage reflects an average of 5 different fields of view, with the number of cells in each field of view ranging from 29 to 116. The indicated error bars reflect the standard deviation from the mean. The statistical significance of differences in the FtsZ and PBP2a phenotypes were analyzed as described in the legend to Fig. 1. n.s., not significant; n.o., none observed.